CN105106931A - 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物 - Google Patents

冻干的或可冻干形式的lkktet和/或lkktnt肽组合物 Download PDF

Info

Publication number
CN105106931A
CN105106931A CN201510532998.4A CN201510532998A CN105106931A CN 105106931 A CN105106931 A CN 105106931A CN 201510532998 A CN201510532998 A CN 201510532998A CN 105106931 A CN105106931 A CN 105106931A
Authority
CN
China
Prior art keywords
peptide
amino acid
agent
lkktnt
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510532998.4A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·克罗克福德
阿兰·L.·戈尔茨坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RegeneRx Biopharmaceuticals Inc
Original Assignee
RegeneRx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RegeneRx Biopharmaceuticals Inc filed Critical RegeneRx Biopharmaceuticals Inc
Priority claimed from CNA2006800216620A external-priority patent/CN101198344A/zh
Publication of CN105106931A publication Critical patent/CN105106931A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
CN201510532998.4A 2005-06-17 2006-06-19 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物 Pending CN105106931A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US69126105P 2005-06-17 2005-06-17
US60/691,261 2005-06-17
US77694706P 2006-02-28 2006-02-28
US60/776,947 2006-02-28
CNA2006800216620A CN101198344A (zh) 2005-06-17 2006-06-19 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800216620A Division CN101198344A (zh) 2005-06-17 2006-06-19 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物

Publications (1)

Publication Number Publication Date
CN105106931A true CN105106931A (zh) 2015-12-02

Family

ID=37570786

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510532998.4A Pending CN105106931A (zh) 2005-06-17 2006-06-19 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物

Country Status (11)

Country Link
US (8) US20090131313A1 (https=)
EP (4) EP1896050A4 (https=)
JP (3) JP2008543878A (https=)
KR (3) KR20080033939A (https=)
CN (1) CN105106931A (https=)
AU (3) AU2006261157A1 (https=)
CA (3) CA2612522A1 (https=)
HK (1) HK1218248A1 (https=)
IL (4) IL187522A0 (https=)
MX (3) MX2007015958A (https=)
WO (3) WO2006138709A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789182A (zh) * 2016-07-18 2019-05-21 雷根特里有限责任公司 治疗干眼综合征的方法
CN110430866A (zh) * 2017-03-03 2019-11-08 Gtreebnt科技有限公司 含有胸腺素β-4作为有效成分的稳定外用剂

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2718774A1 (en) * 2008-03-17 2009-12-17 Regenerx Biopharmaceuticals, Inc. Improved beta thymosin fragments
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
WO2011044589A2 (en) * 2009-10-09 2011-04-14 Board Of Regents, The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
DK2819682T3 (en) 2012-03-01 2017-08-21 Firststring Res Inc TOPICAL GELLS CONTAINING ALPHA-CONNEXIN C-TERMINAL (ACT) PEPTIDES
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
AU2014345802B2 (en) * 2013-11-07 2018-01-25 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Storage stable lyophilized tripeptide formulations
CA2942035A1 (en) 2014-03-12 2015-09-17 University Of Virginia Patent Foundation Compositions and methods for treating eye infections and disease
WO2016064078A1 (ko) 2014-10-22 2016-04-28 주식회사 지트리비앤티 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US9867868B2 (en) 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
KR20170021667A (ko) 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
JP6996713B2 (ja) * 2015-10-06 2022-02-04 エイチエルビー・セラピューティクス・カンパニー・リミテッド チモシンベータ４を含む眼科用製剤の製造方法
KR102115158B1 (ko) 2016-11-29 2020-05-26 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
KR20250023579A (ko) * 2017-02-21 2025-02-18 티얼솔루션즈, 인크. 안정한 펩타이드 조성물
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
US10342824B2 (en) 2017-07-17 2019-07-09 Dr. Marlowe's Weight Loss Institute, P.L.L.C. Supplement for treating side effects of medications which cause metabolic acidosis
CN111386337A (zh) * 2017-11-24 2020-07-07 Gtreebnt科技有限公司 包含胸腺素β4或其衍生物作为活性成分的用于促进杯状细胞增殖或粘蛋白分泌的组合物
MX2023004631A (es) 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.
WO2024006653A2 (en) * 2022-07-01 2024-01-04 Tearsolutions, Inc. Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006190A1 (en) * 1998-07-30 2000-02-10 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health THYMOSIN β4 PROMOTES WOUND REPAIR
US20040131626A1 (en) * 2001-03-15 2004-07-08 Goldstein Allan L. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (tb4) analogues, isoforms and other derivatives
WO2004091550A2 (en) * 2003-03-31 2004-10-28 Regenerx Biopharmaceuticals, Inc. Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
US20040258680A1 (en) * 2001-08-29 2004-12-23 Goldstein Allan L. Methos of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogoues, isoforms and other derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5564345A (en) 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
CA2132826C (en) * 1992-05-06 1999-01-05 Masood Chowhan Use of borate-polyol complexes in ophthalmic compositions
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
AU3070395A (en) 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
WO2002024234A2 (en) * 2000-09-20 2002-03-28 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US20040005644A1 (en) * 2002-02-28 2004-01-08 Su Yan A. Method and composition for detection and treatment of breast cancer
CA2497977A1 (en) * 2002-09-20 2004-04-01 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
WO2004099768A1 (en) * 2003-05-05 2004-11-18 Regenerx Biopharmaceuticals, Inc. Method for detecting development of a physiological disorder in a subject
CN108738377B (zh) 2015-07-30 2020-11-10 株式会社半导体能源研究所 发光装置的制造方法、发光装置、模块及电子设备

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006190A1 (en) * 1998-07-30 2000-02-10 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health THYMOSIN β4 PROMOTES WOUND REPAIR
US20040131626A1 (en) * 2001-03-15 2004-07-08 Goldstein Allan L. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (tb4) analogues, isoforms and other derivatives
US20040258680A1 (en) * 2001-08-29 2004-12-23 Goldstein Allan L. Methos of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogoues, isoforms and other derivatives
WO2004091550A2 (en) * 2003-03-31 2004-10-28 Regenerx Biopharmaceuticals, Inc. Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GABRIEL SOSNE ET AL.: "Thymosin-β4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro", 《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE》 *
LARRY WHEELER ET AL.: "Role of Alpha-2 Agonists in Neuroprotection", 《SURVEY OF OPHTHALMOLOGY》 *
STEVEN YEB ET AL.: "Apoptosis of ocular surface cells in experimentally induced dry eye", 《STEVEN YEB ET AL.》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789182A (zh) * 2016-07-18 2019-05-21 雷根特里有限责任公司 治疗干眼综合征的方法
CN110430866A (zh) * 2017-03-03 2019-11-08 Gtreebnt科技有限公司 含有胸腺素β-4作为有效成分的稳定外用剂
CN110430866B (zh) * 2017-03-03 2023-04-07 Hlb医疗有限公司 含有胸腺素β-4作为有效成分的稳定外用剂

Also Published As

Publication number Publication date
US20090131313A1 (en) 2009-05-21
AU2006261157A1 (en) 2006-12-28
CA2612410A1 (en) 2006-12-28
WO2006138708A1 (en) 2006-12-28
WO2006138709A2 (en) 2006-12-28
IL218504A (en) 2013-10-31
US20170128540A1 (en) 2017-05-11
JP2008543878A (ja) 2008-12-04
JP2008543879A (ja) 2008-12-04
MX2007015958A (es) 2008-04-17
US20120071411A1 (en) 2012-03-22
US20090118196A1 (en) 2009-05-07
IL218504A0 (en) 2012-04-30
IL187781A0 (en) 2008-08-07
IL187522A0 (en) 2008-03-20
US20160193301A1 (en) 2016-07-07
AU2006261155A1 (en) 2006-12-28
US9821030B2 (en) 2017-11-21
CA2612405A1 (en) 2006-12-28
KR20080021782A (ko) 2008-03-07
MX2007015956A (es) 2008-03-06
US20180028619A1 (en) 2018-02-01
IL187617A0 (en) 2008-03-20
EP1896050A2 (en) 2008-03-12
EP1906986A1 (en) 2008-04-09
KR20080033939A (ko) 2008-04-17
US9585941B2 (en) 2017-03-07
EP1904080A1 (en) 2008-04-02
US8383576B2 (en) 2013-02-26
US20160287673A1 (en) 2016-10-06
JP2008543877A (ja) 2008-12-04
WO2006138708B1 (en) 2007-04-05
EP1896050A4 (en) 2010-01-27
US10004785B2 (en) 2018-06-26
WO2006138709A3 (en) 2007-07-05
IL187781A (en) 2012-04-30
WO2006138707A1 (en) 2006-12-28
AU2006261156A1 (en) 2006-12-28
EP1906986A4 (en) 2011-02-23
EP3326647A1 (en) 2018-05-30
AU2006261156B2 (en) 2012-05-31
CA2612522A1 (en) 2006-12-28
US20080214456A1 (en) 2008-09-04
HK1218248A1 (zh) 2017-02-10
KR20080018268A (ko) 2008-02-27
MX2007015957A (es) 2008-03-06
EP1904080A4 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
US10004785B2 (en) LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
US12064469B2 (en) Stable peptide compositions
WO2008108927A2 (en) Methods and compositions for stabilizing polypeptides
CN101198344A (zh) 冻干的或可冻干形式的lkktet和/或lkktnt肽组合物
HK1256177A1 (en) Lkktet and/or lkktnt peptide compositions which are lyophilized or in a form capable of being lyophilized
WO2024006653A2 (en) Stable peptide compositions and methods of use thereof for treatment of moderate/severe dry eye-related ocular symptoms

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1218248

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1218248

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20151202

RJ01 Rejection of invention patent application after publication